Concepedia

Herman Burger

HB

Statistics

Publications

31

Citations

2.8K

H-Index

26

Active since

1987

Affiliations

Erasmus MC(Current)

Erasmus MC Cancer Institute

Rotterdam University of Applied Sciences

Meertens Institute

Erasmus University Rotterdam

Herman Burger is an author at Erasmus MC specializing in oncology, medicine, and pharmacology.

Publications per year

1987–2017

31

Publications

31

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

Herman Burger, Hans van Tol, Antonius W.M. Boersma et al. · Blood · 2004 · 415 citations · Full text

, , +11

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

Herman Burger, John A. Foekens, Maxime P. Look et al. · PubMed · 2003 · 293 citations · Full text

, , +17

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

Ferry A.L.M. Eskens, Francisco Javier Ramos, Herman Burger et al. · Clinical Cancer Research · 2013 · 250 citations · Full text

, , +14

Interaction of Imatinib with Human Organic Ion Carriers

Shuiying Hu, Ryan M. Franke, Kelly K. Filipski et al. · Clinical Cancer Research · 2008 · 232 citations · Full text

, , +17

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

Herman Burger, Hans van Tol, Mariël Brok et al. · Cancer Biology & Therapy · 2005 · 204 citations · Full text

, , +15

1–5 of 31